ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2019
Pertactin-deficient
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Pertactin deficiency ofHuman vaccines & immunotherapeutics · 2024Pooled it
- Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.Frontiers in immunology · 2022Trial
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- Comparing frequentist and Bayesian methods to identify drivers of pathogen strain invasion: A temporal case study of pertussis in the United States.Infectious Disease Modelling · 2026Article
- Development of High-Throughput Serum Bactericidal Assays forVaccines · 2026Article
- Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry.Chemical science · 2026Article
- Laboratory diagnosis of pertussis: A survey on provincial public health laboratory methods.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- The evolution of pertactin expression in Belgian circulatingMicrobiology spectrum · 2026Article
- Antibody waning and Bordetella pertussis resurgence after the COVID-19 pandemic in the Netherlands.Nature communications · 2026Article
- CD4+ T-cell immunity toDiscover immunity · 2026Review
- No innocent bystanders: pertussis vaccination and evolutionary parallelisms betweenMicrobial genomics · 2025Article
- Pertussis-A Re-Emerging Threat Despite Immunization: An Analysis of Vaccine Effectiveness and Antibiotic Resistance.International journal of molecular sciences · 2025Review
- Variation in virulence between three representativemSphere · 2025Article
- Vaccine antigen-based genotyping ofMicrobiology spectrum · 2025Article
- Pertussis before, during and after Covid-19.EMBO molecular medicine · 2025Review
- Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management.Infection & chemotherapy · 2025Review
- Pertussis resurgence: epidemiological trends, pathogenic mechanisms, and preventive strategies.Frontiers in immunology · 2025Review
- Understanding the impact of adult pertussis and current approaches to vaccination: A narrative review and expert panel recommendations.Human vaccines & immunotherapeutics · 2024Review
- Macrolide-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Prevalence of Pertactin-Deficient Bordetella pertussis Isolates, Slovenia.Emerging infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 12 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionPertussis outbreaks have occurred in several industrialised countries using acellular pertussis vaccines (ACVs) since the 1990s. High prevalence of pertactin (PRN)-deficient
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.